Retrospective analysis of the HIV-1 reverse transcriptase inhibitors' resistance in Silesia, Poland

Medical Science Monitor

Volumn 17, Issue 2, 2011, Pages

  Smoleń, Joanna ^a   Kruszyński, Piotr ^a   Bratosiewicz Wasik, Jolanta ^a   Witor, Adam ^b   Wasik, Tomasz J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Specialistic Hospital in Chorzow   (Poland)

Author keywords

HIV 1 drug resistance; Pol gene; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CODON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLAND; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL GENE;

EID: 79551705092     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881384     Document Type: Article

References (34)

1. National Institute of Public Health, National Institute of Hygiene. Epidemiological reports. http://www.pzh.gov.pl; last assessed: 08.02.2010.
2. Rosinska M, Werbinska-Sienkiewicz B: AIDS and HIV infection in Poland in 2003. Przegl Epidemiol, 2005; 59: 337-48
3. http://www.aids.gov.pl; last assessed: 08.02.2010.
4. Szata W: AIDS and HIV infection in Poland in 2000. Przegl Epidemiol 2002; 56: 363-73
5. Jablonowska E, Malolepsza E: Profile of patients with newly diagnosed HIV in the Lódz region in Poland from 1996 to 2005. Arch Med Sci, 2009; 5: 577-82
6. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science, 1995; 267: 483-89
7. Little SJ: Transmission and prevalence of HIV resistance among treatment- naive subjects. Antivir Ther, 2000; 5: 33-40
8. Little SJ, Frost SDW, Wong JK et al: Persistence of transmitted drug-resistance among subjects with primary human immunodeficiency virus infection. J Virol, 2008; 82: 5510-18
9. The SPREAD programme 2008. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS, 2008; 22: 625-35
10. Richman DD: HIV chemotherapy. Nature, 2001; 410: 995-1001
11. Wolf E: HIV resistance testing. In: Hoffman C, Rockstroh JK, Kamps BS (eds.), HIV Medicine 2007. Paris, Cagliari, Wupertal: Flying Publishers, 2007; 321-52
12. Wensing AM, van de Vijver DA, Angarano G et al: Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis, 2005; 192: 958-66
13. Hoffman C, Mulcahy F: Overview of antiretroviral drugs. In: Hoffman C, Rockstroh JK, Kamps BS, editors. HIV Medicine 2007. Paris, Cagliari, Wupertal: Flying Publishers, 2007; 93-126
14. Johnson VA, Brun-Vezinet F, Clotet B et al: Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med, 2007; 15: 119-25
15. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, New York, 1989; 16-21
16. Izopet J, Salama G, Pasquier C et al: Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol, 1998; 19: 478-83
17. HIV Drug Resistance Database. Stanford University. http://hivdb.stanford.edu
18. Available from: http://www.ncbi.nih.gov/projects/genotyping/formpage.cgi
19. Rozanov M, Plikat U, Chappey C et al: A web-based genotyping resource for viral sequences. Nucleic Acids Res, 2004; 32: 654-59
20. Available from: Los Alamos National Laboratory. http://www.hiv.lanl.gov
21. Rose PP, Korber BT: Detecting hypermutations in viral sequences with an emphasis on G->A hypermutation. Bioinformatics, 2000; 16: 400-1
22. Clumeck N, Pozniak A, Raffi F: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Medicine, 2008; 9: 65-71
23. Brenner B, Turner D, Oliveira M et al: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS, 2003; 17: F1-5
24. Vandamme AM, Sonnerborg M, Ait-Khaled J et al: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther, 2004; 9: 829-48
25. Descamps D, Collin G, Letourneur F et al: Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol, 1997; 71: 8893-98
26. Loemba H, Brenner B, Parniak MA et al: Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother, 2002; 46: 2087-94
27. Gao Y, Paxinos F, Galovich J et al: Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors. J Virol, 2004; 78: 5390-401
28. Graham SM: Clinical impact of HIV-1 subtype: are there important differences? Future HIV Ther, 2007; 1: 273-90
29. Camacho RJ, Vandamme AM: Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. Current Opinion in HIV & AIDS, 2007; 2: 123-29
30. Kantor R, Katzenstein DA, Efron B et al: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a Global Collaboration. PloS Medicine, 2005; 2: 325-37
31. Meyer PR, Matsuura SE, Schinazi RF et al: Differential removal of thymidine nucleotide analogues from blocked DNA chains by HIV reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother, 2000; 44: 3465-72
32. Shafer RW, Dupnik K, Winters MA, Eshleman SH: A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. In: Kuiken C, Foley B, Hahn B et al, (eds.), HIV sequence compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2001; 1-51. Available from: URL: http:// www.hiv.lanl.gov/content/hivdb/COMPENDIUM/2001/partI/Shafer.pdf
33. Cane P, Chrystie I, Dunn D et al: Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ, 2005; 331: 1368-73
34. Stańczak GP, Stanczak JJ, Firlag-Burkacka E et al: Transmission of HIV-1 drug resistance among newly diagnosed patients in Poland. Przegl Epidemiol, 2007; 61: 29-34